Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford, UK.
Curr Opin Clin Nutr Metab Care. 2013 Mar;16(2):225-31. doi: 10.1097/MCO.0b013e32835d2edf.
The fatty acid, palmitoleate (16:1 n - 7), has received a lot of attention in recent years for being 'lipokine' and for the first time, we review the evidence to determine if there is something special about palmitoleate in humans.
Despite dietary intakes being low (<4% of total energy) palmitoleate is the second most abundant monounsaturated fatty acid in most, but not all, blood lipid pools and notably more abundant in adipose tissue. Thus, compared with other fatty acids, the palmitoleate content of lipid pools must be influenced by endogenous synthesis, which appears to be tissue and depot specific. We present a summary of dietary intervention studies of food components enriched in palmitoleate but this gives inconclusive results in regards to an impact on human metabolic regulation.
To date, there is no strong evidence from human studies suggesting that palmitoleate has 'lipokine' effects. However, unlike other fatty acids, there is a clear tendency towards compartmentalization and tissue-specific formation of palmitoleate, which is intriguing and requires further investigation.
近年来，脂肪酸棕榈油酸（16:1n-7）作为一种“脂肪因子”备受关注，我们首次对其相关证据进行了综述，以确定其在人类中是否有特殊之处。
尽管饮食摄入量低（<4%总能量），但棕榈油酸是大多数（并非所有）血脂库中第二丰富的单不饱和脂肪酸，在脂肪组织中尤为丰富。因此，与其他脂肪酸相比，脂库中棕榈油酸的含量必然受到内源性合成的影响，而内源性合成似乎具有组织和脂肪库特异性。我们总结了富含棕榈油酸的食物成分的饮食干预研究，但这些研究结果尚不能确定其对人体代谢调节的影响。
迄今为止，尚无强有力的人体研究证据表明棕榈油酸具有“脂肪因子”作用。然而，与其他脂肪酸不同，棕榈油酸具有明显的分区化和组织特异性形成趋势，这令人好奇，需要进一步研究。
